Safety of DS-1040b in Acute Ischemic Stroke Patients Treated With Thrombectomy
Launched by DAIICHI SANKYO CO., LTD. · Jun 22, 2017
Trial Information
Current as of August 02, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Is an acute ischemic stroke patients with evidence of intracranial vascular occlusion
- • Is enrolled in principle within 8 hours of symptom onset
- • Has treatment plan that includes stent retriever
- • Has protocol-defined scores on several scales
- Exclusion Criteria:
- • Has treatment plan that includes fibrinolysis or fibinolysis
- • Has identified intracranial hemorrhage or subarachnoid hemorrhage
- • Has active bleeding like gastrointestinal hemorrhage
- • Has cerebral bleeding risk; intracranial tumor, brain aneurysm, cerebral arteriovenous malformation, or history of intracranial bleeding
- • Has severe hepatic or renal impairment
- • Has been a participant in other clinical trial within 30 days prior to treatment
- • Is pregnant, lactating, or planning on becoming pregnant during treatment period
- * Has any condition or history that might, per protocol or in the opinion of the investigator, compromise:
- • 1. safety or well-being of the participant or their offspring
- • 2. safety of the study staff
- • 3. analysis of results
About Daiichi Sankyo Co., Ltd.
Daiichi Sankyo Co., Ltd. is a global healthcare company headquartered in Tokyo, Japan, renowned for its commitment to innovative research and development in pharmaceuticals. With a rich history spanning over a century, the company focuses on delivering transformative treatments across various therapeutic areas, including oncology, cardiovascular disease, and infectious diseases. Daiichi Sankyo leverages cutting-edge science and technology to advance its drug development pipeline, emphasizing collaboration and partnership to enhance patient outcomes worldwide. Its dedication to improving global health is reflected in its extensive clinical trials, which aim to bring novel therapies to market and address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tsu, Mie, Japan
Morioka, Iwate, Japan
Sapporo, Hokkaido, Japan
Ube, Yamaguchi, Japan
Hidaka, Saitama, Japan
Wakayama, , Japan
Kobe, Hyogo, Japan
Niigata, , Japan
Suita, Osaka, Japan
Yokohama, Kanagawa, Japan
Tsukuba, Ibaraki, Japan
Hiroshima, , Japan
Hirosaki, Aomori, Japan
Funabashi, Chiba, Japan
Kitakyushu, Fukuota, Japan
Isesaki, Gunma, Japan
Amagasaki, Hyogo, Japan
Nishinomiya, Hyogo, Japan
Odawara, Kanagawa, Japan
Nagasaki, , Japan
Patients applied
Trial Officials
Global Clinical Leader
Study Director
Daiichi Sankyo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials